Lupus trials recruiting in North Carolina

All Lupus trials nationally

Cities in North Carolina

Recruiting trials in North Carolina

• A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
  NCT06308978 · Phase: Phase 1 · Ages: 12 Years to 70 Years · Sex: All (male and female) · North Carolina: Durham
• A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
  NCT07570862 · Phase: Phase 2 · Ages: 12 Years to 70 Years · Sex: All (male and female) · North Carolina: Fayetteville
• A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
  NCT06925542 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
  NCT06411249 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Winston-Salem
• A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
  NCT07175285 · Phase: Not specified · Ages: 16 Years and older · Sex: All (male and female) · North Carolina: Charlotte, Durham
• A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
  NCT07355218 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Charlotte, Smithfield
• A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
  NCT07115745 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
  NCT07438496 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Charlotte, Fayetteville
• A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
  NCT06581198 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Durham
• A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
  NCT06617325 · Phase: Phase 3 · Ages: 16 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
  NCT06916806 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
  NCT07085104 · Phase: Phase 1 · Ages: 18 Years to 74 Years · Sex: All (male and female) · North Carolina: Charlotte, Durham
• A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
  NCT06897930 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · North Carolina: Chapel Hill, Charlotte
• A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
  NCT07409181 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · North Carolina: Charlotte, Fayetteville
• An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
  NCT05835310 · Phase: Phase 3 · Ages: 5 Years to 17 Years · Sex: All (male and female) · North Carolina: Durham
• Anifrolumab Pregnancy Study
  NCT07049653 · Phase: Not specified · Ages: 18 Years to 130 Years · Sex: Female · North Carolina: Cary
• Duke Lupus Registry
  NCT00512694 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Durham
• Intervention to Improve Communication and Medication Adherence in Lupus
  NCT06458075 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 90 Years · Sex: All (male and female) · North Carolina: Durham
• Lupus Landmark Study: A Prospective Registry and Biorepository
  NCT05934149 · Phase: Not specified · Ages: 18 Years to 110 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• Maternal Autoimmune Disease Research Alliance (MADRA) Registry
  NCT03276923 · Phase: Not specified · Ages: No age limits stated · Sex: Female · North Carolina: Durham
• PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
  NCT07611214 · Phase: Phase 4 · Ages: 18 Years to 75 Years · Sex: All (male and female) · North Carolina: Charlotte
• Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users
  NCT06659029 · Phase: Not specified · Ages: No age limits stated · Sex: Female · North Carolina: Wilmington
• RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
  NCT06121297 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · North Carolina: Chapel Hill
• Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
  NCT06527872 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · North Carolina: Charlotte
• The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
  NCT05538208 · Phase: Phase 2 · Ages: 8 Years to 20 Years · Sex: All (male and female) · North Carolina: Chapel Hill